Divalent metal transporter 1 expression and iron deposition in the substantia nigra of a rat model of Parkinson's disease

Neural Regeneration Research

Volumn 5, Issue 22, 2010, Pages 1701-1705

  Song, Yangwen ^a   Chen, Xin ^a   Li, Chun ^a   Zhang, Nan ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Animal models; Divalent metal transporter 1; Iron; Neurodegenerative disease; Parkinson's disease; Rotenone

Indexed keywords

FERRIC FERROCYANIDE; IRON; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 2; TYROSINE 3 MONOOXYGENASE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN SLICE; CONTROLLED STUDY; FROZEN SECTION; IRON STORAGE; MALE; MESENCEPHALON; NONHUMAN; PARKINSON DISEASE; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; SCORING SYSTEM; STAINING; SUBSTANTIA NIGRA;

EID: 78651448961     PISSN: 16735374     EISSN: None     Source Type: Journal    
DOI: 10.3969/j.issn.1673-5374.2010.22.003     Document Type: Article

References (31)

1. Zecca L, Youdim MB, Riederer P, et al. Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci. 2004;5(11): 863-873.
2. Haacke EM, Cheng NY, House MJ, et al. Imaging iron stores in the brain using magnetic resonance imaging. Magn Reson Imaging. 2005;23(1):1-25.
3. Götz ME, Double K, Gerlach M, et al. The relevance of iron in the pathogenesis of Parkinson's disease. Ann N Y Acad Sci. 2004; 1012:193-208.
4. Martin WR, Wieler M, Gee M. Midbrain iron content in early Parkinson disease: a potential biomarker of disease status. Neurology. 2008;70(16 Pt 2):1411-1417.
5. Galazka-Friedman J. Iron as a risk factor in neurological diseases. Hyperfine Interact. 2008;182(1-3):31-44.
6. Castellani RJ, Siedlak SL, Perry G, et al. Sequestration of iron by Lewy bodies in Parkinson's disease. Acta Neuropathol. 2000; 100(2):111-114.
7. Bharathi, Indi SS, Rao KS. Copper-and iron-induced differential fibril formation in alpha-Synuclein: TEM study. Neurosci Lett. 2007; 424(2):78-82.
8. Kaur D, Andersen J. Does cellular iron dysregulation play a causative role in Parkinson's disease. Ageing Res Rev. 2004;3(3): 327-343.
9. He Y, Lee T, Leong SK. Time course of dopaminergic cell death and changes in iron, ferritin and transferrin levels in the rat substantia nigra after 6-hydroxydopamine (6-OHDA) lesioning. Free Radic Res. 1999;31(2):103-112.
10. He Y, Thong PS, Lee T, et al. Dopaminergic cell death precedes iron elevation in MPTP-injected monkeys. Free Radic Biol Med. 2003;35(5):540-547.
11. Lee DW, Andersen JK, Kaur D. Iron dysregulation and neurodegeneration: The molecular connection. Mol Interv. 2006; 6(2):89-97.
12. Ke Y, Chang YZ, Duan XL, et al. Age-dependent and iron-independent expression of two mRNA isoforms of divalent metal transporter 1 in rat brain. Neurobiol Aging. 2005;26(5): 739-748.
13. Ke Y, Qian ZM. Brain iron metabolism: Neurobiology and neurochemistry. Prog Neurobiol. 2007;83(3):149-173.
14. Jiang H, Song N, Wang J, et al. Peripheral iron dextran induced degeneration of dopaminergic neurons in rat substantia nigra. Neurochem Int. 2007;51(1):32-36.
15. Gruenheid S, Cellier M, Vidal S, et al. Identification and characterization of a second mouse Nramp gene. Genomics. 1995;25(2):514-525.
16. Fleming MD, Trenor CC 3rd, Su MA, et al. Microcytic anaemia mice have a mutation in Nramp2, a candidate iron transporter gene. Nat Genet. 1997;16(4):383-386.
17. Gunshin H, Mackenzie B, Berger UV, et al. Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature. 1997;388(6641):482-488.
18. Ke Y, Ming Qian Z. Iron misregulation in the brain: a primary cause of neurodegenerative disorders. Lancet Neurol. 2003;2(4): 246-253.
19. Jiang H, Qian ZM, Xie JX. Increased DMT1 expression and iron content in MPTP-treated C57BL/6 mice. Sheng Li Xue Bao. 2003;55(5):571-576.
20. Chen X, Zhang N, Zhao H, et al. The relations of behavioral features and loss of Nigrostriatum on the model of Parkinsons disease induced by rotenone on rats. Zhongguo Jingshen Shenjing Zazhi. 2008;34(4):232-234.
21. Chen X, Zhang N, Li C. Changes of mitochondrial respiratory chain complex I and complex IV activity in rotenone-induced rat model of Parkinson's disease. Acta Lab Anim Sci Sin. 2009;17(2): 135-137.
22. Mastroberardino PG, Hoffman EK, Horowitz MP, et al. A novel transferrin TfR2-mediated mitochondrial iron transport system is disrupted in Parkinson's disease. Neurobiol Dis. 2009;34(3): 417-431.
23. Berg D, Hochstrasser H, Schweitzer KJ, et al. Disturbance of iron metabolism in Parkinson's disease: ultrasonography as a biomarker. Neurotox Res. 2006;9(1):1-13.
24. Berg D. Disturbance of iron metabolism as a contributing factor to SN hyperechogenicity in Parkinson's disease: Implications for idiopathic and monogenetic forms. Neurochem Res. 2007;32(10): 1646-1654.
25. Valerio LG. Mammalian iron metabolism. Toxicol Mech Methods. 2007;17(9):497-517.
26. Ke Y, Qian ZM. Divalent metal transporter 1: A newly discovered mammalian iron transporter protein. Shengwu Huaxue yu Shenwu Wuli Jinzhan. 2002;29(2):184-188.
27. Chen X, Zhang N, Zhao H, et al. The protect effect of Baicalin on the substantial nigra dopaminergic neuron in Parkinson's rats induced by rotenone. Zhongfeng yu Shenjing Jibing Zazhi. 2008; 25(2):174-177.
28. Zhang L, Zhu L. Inhibitors of respiratory chain change the expression of DMT1 in HepG2 Cells. Jiangsu Daxue Xuebao: Yixue Ban. 2006;16(2):101-104.
29. The Ministry of Science and Technology of the People's Republic of China. Guidance Suggestions for the Care and Use of Laboratory Animals. 2006-09-30.
30. Gomes MZ, Raisman-Vozari R, Del Bel EA. A nitric oxide synthase inhibitor decreases 6-hydroxydopamine effects on tyrosine hydroxylase and neuronal nitric oxide synthase in the rat nigrostriatal pathway. Brain Res. 2008;1203:160-169.
31. Jiang H, Luan Z, Wang J, et al. Neuroprotective effects of iron chelator desferal on dopaminergic neurons in the substantia nigra of rats with iron-overload. Neurochem Int. 2006;49(6):605-609.